Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Payables (2016 - 2026)

Veracyte's Payables history spans 14 years, with the latest figure at $4.6 million for Q4 2025.

  • On a quarterly basis, Payables fell 46.8% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a 46.8% decrease, with the full-year FY2025 number at $4.6 million, down 46.8% from a year prior.
  • Payables hit $4.6 million in Q4 2025 for Veracyte, down from $5.5 million in the prior quarter.
  • Over the last five years, Payables for VCYT hit a ceiling of $15.7 million in Q1 2025 and a floor of $4.6 million in Q4 2025.
  • Historically, Payables has averaged $10.9 million across 5 years, with a median of $11.4 million in 2022.
  • Biggest five-year swings in Payables: soared 479.76% in 2021 and later crashed 46.8% in 2025.
  • Tracing VCYT's Payables over 5 years: stood at $12.4 million in 2021, then fell by 3.63% to $11.9 million in 2022, then rose by 8.66% to $12.9 million in 2023, then crashed by 33.29% to $8.6 million in 2024, then crashed by 46.8% to $4.6 million in 2025.
  • Business Quant data shows Payables for VCYT at $4.6 million in Q4 2025, $5.5 million in Q3 2025, and $11.4 million in Q2 2025.